Nursing

Adaptive Research and AHMC Seton Medical Center Announce Collaboration to Expand Clinical Trial Access to Both In- and Out-Patient Settings

SAN FRANCISCO and DALY CITY, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- Adaptive Research, an integrated clinical trial site organization…

1 year ago

Medical City Frisco is the Latest Hospital to Utilize Surgalign’s HOLO Portal Surgical Guidance System

This represents the first site in Texas; Medical City Frisco to leverage the benefits of HOLO Portal, the world’s first…

1 year ago

Rhythm Pharmaceuticals Announces Acquisition of Xinvento B.V. and Portfolio of Investigational Therapeutics

       - Rare disease company in preclinical development for congenital hyperinsulinism - - Acquisition is strong strategic fit…

1 year ago

Creative Health Care Management Joins the ANPD Aspire Conference 2023

CHCM Will Conduct the Ultimate Competency Assessment WorkshopAtlanta, GA, Feb. 22, 2023 (GLOBE NEWSWIRE) -- From March 14 to 17,…

1 year ago

Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Wednesday, March 1, 2023

BOSTON, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the…

1 year ago

Philips and TriHealth announce multi-year partnership at heart of new TriHealth Heart & Vascular Institute on the campus of Bethesda North Hospital

Cardiac interventional suite at TriHealth Heart & Vascular Institute on the campus at Bethesda North Exam room in the cardiac…

1 year ago

Amedisys Announces Fourth Quarter and Year End Earnings Release and Conference Call Dates

BATON ROUGE, La., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of quality home health,…

1 year ago

Catalyst Pharmaceuticals Completes the Acquisition of U.S. Rights to FYCOMPA® (Perampanel) CIII

Strengthens its Commercial Portfolio with the First and Only AMPA Receptor Antagonist Marketed Product for Epilepsy Bolsters Presence in Neuroscience…

1 year ago

Rhythm Pharmaceuticals Announces Publication of Analysis of Quality of Life Improvements from Phase 3 Clinical Trial in Bardet-Biedl Syndrome

- Patients reported clinically meaningful improvements across multiple health-related quality of life measures following 52 weeks of treatment with setmelanotide…

1 year ago

Assertio Announces Partnership with the Lennox-Gastaut Syndrome (LGS) Foundation

SYMPAZAN® (clobazam) oral film from Assertio is used for the adjunctive treatment of seizures associated with LGS in patients two…

2 years ago